BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34506231)

  • 1. Resveratrol-modified mesoporous silica nanoparticle for tumor-targeted therapy of gastric cancer.
    Lin M; Yao W; Xiao Y; Dong Z; Huang W; Zhang F; Zhou X; Liang M
    Bioengineered; 2021 Dec; 12(1):6343-6353. PubMed ID: 34506231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesoporous Silica Nanoparticles Loaded with Resveratrol Are Used for Targeted Breast Cancer Therapy.
    Gu Y; Fei Z
    J Oncol; 2022; 2022():8471331. PubMed ID: 36245986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery and apoptosis induction activity of peptide-transferrin targeted mesoporous silica encapsulated resveratrol in MCF-7 cells.
    Li D; Song C; Zhang J; Zhao X
    J Pharm Pharmacol; 2023 Jan; 75(1):49-56. PubMed ID: 36173891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-miRNA21 and resveratrol-loaded polysaccharide-based mesoporous silica nanoparticle for synergistic activity in gastric carcinoma.
    Hu Y; Wang Z; Qiu Y; Liu Y; Ding M; Zhang Y
    J Drug Target; 2019 Dec; 27(10):1135-1143. PubMed ID: 31017473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gold Nanoparticles Functionalized with Au-Se-Bonded Peptides Used as Gatekeepers for the Off-Target Release of Resveratrol in the Treatment of Triple-Negative Breast Cancer.
    Liu X; Liu J; Xu S; Li X; Wang Z; Gao X; Tang B; Xu K
    ACS Appl Mater Interfaces; 2023 Jan; 15(2):2529-2537. PubMed ID: 36595474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasound-Triggered Destruction of Folate-Functionalized Mesoporous Silica Nanoparticle-Loaded Microbubble for Targeted Tumor Therapy.
    Lv Y; Cao Y; Li P; Liu J; Chen H; Hu W; Zhang L
    Adv Healthc Mater; 2017 Sep; 6(18):. PubMed ID: 28671341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin-loaded redox-responsive mesoporous silica nanoparticles for targeted breast cancer therapy.
    Li N; Wang Z; Zhang Y; Zhang K; Xie J; Liu Y; Li W; Feng N
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):921-935. PubMed ID: 29790797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A focal adhesion kinase inhibitor 16-hydroxy-cleroda-3,13-dien-16,15-olide incorporated into enteric-coated nanoparticles for controlled anti-glioma drug delivery.
    Thiyagarajan V; Lin SX; Lee CH; Weng CF
    Colloids Surf B Biointerfaces; 2016 May; 141():120-131. PubMed ID: 26851441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
    Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A composite hydrogel containing resveratrol-laden nanoparticles and platelet-derived extracellular vesicles promotes wound healing in diabetic mice.
    Zhu W; Dong Y; Xu P; Pan Q; Jia K; Jin P; Zhou M; Xu Y; Guo R; Cheng B
    Acta Biomater; 2022 Dec; 154():212-230. PubMed ID: 36309190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy.
    Sun JG; Jiang Q; Zhang XP; Shan K; Liu BH; Zhao C; Yan B
    Int J Nanomedicine; 2019; 14():1489-1501. PubMed ID: 30880960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of L-tartaric Acid Modified Chiral Mesoporous Silica Nanoparticle as a Drug Carrier: Structure, Wettability, Degradation, Bio-Adhesion and Biocompatibility.
    Hu B; Wang J; Li J; Li S; Li H
    Int J Nanomedicine; 2020; 15():601-618. PubMed ID: 32099354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells.
    Sarkar A; Ghosh S; Chowdhury S; Pandey B; Sil PC
    Biochim Biophys Acta; 2016 Oct; 1860(10):2065-75. PubMed ID: 27392941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
    Choi JY; Ramasamy T; Kim SY; Kim J; Ku SK; Youn YS; Kim JR; Jeong JH; Choi HG; Yong CS; Kim JO
    Acta Biomater; 2016 Jul; 39():94-105. PubMed ID: 27163403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
    Yan Y; Fu J; Wang T; Lu X
    Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Facile Way for Fabricating PEGylated Hollow Mesoporous Silica Nanoparticles and Their Drug Delivery Application.
    Teng X; Cheng S; Meng R; Zheng S; Yang L; Ma Q; Jiang W; He J
    J Nanosci Nanotechnol; 2015 May; 15(5):3773-9. PubMed ID: 26505004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dual-sensitive mesoporous silica nanoparticle based drug carrier for cancer synergetic therapy.
    Zhang J; Shen B; Chen L; Chen L; Meng Y; Feng J
    Colloids Surf B Biointerfaces; 2019 Mar; 175():65-72. PubMed ID: 30522009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of IL-13 Receptor α2-Targeting Resveratrol Nanoparticles against Glioblastoma Cells: Therapeutic Efficacy and Molecular Effects.
    Lin XM; Shi XX; Xiong L; Nie JH; Ye HS; Du JZ; Liu J
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
    Lv Y; Li J; Chen H; Bai Y; Zhang L
    Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.
    Wu D; Zhu ZQ; Tang HX; Shi ZE; Kang J; Liu Q; Qi J
    Theranostics; 2020; 10(21):9808-9829. PubMed ID: 32863961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.